Study guide

18.3 Process (Behavioral) Addictions: Gambling Disorder, Gaming & Compulsive Behaviors

Certified Addictions Registered Nurse - Advanced Practice CARN-AP

Track your progress as you read

Finished sections get a check mark.

1 Introduction: The CARN-AP Examination & Foundations of Advanced Addictions Practice

About the CARN-AP Examination: Blueprint, Scoring & Eligibility The Neurobiology of Addiction: Binge, Withdrawal & Preoccupation Screening, SBIRT & the ASAM Criteria Levels of Care

2 Chapter 1: Opioid Use Disorder: Assessment, Overdose Response & Methadone Maintenance

1.1 OUD Assessment, DSM-5-TR Diagnostic Criteria, and Clinical Opiate Withdrawal Scale (COWS) 1.2 Methadone Pharmacology, OTP Federal Regulations, QTc Prolongation & CYP450 Interactions 1.3 Opioid Overdose Assessment, Harm Reduction, Naloxone Formulations & Nalmefene

3 Chapter 2: Buprenorphine Protocols, Long-Acting Injectables & Naltrexone

2.1 Buprenorphine Pharmacology, Standard Office/Home Induction & Precipitated Withdrawal Management 2.2 Low-Dose Micro-Induction (Bernese Method) & Fentanyl Transition Strategies 2.3 Long-Acting Injectable Buprenorphine (Sublocade, Brixadi) & Extended-Release Naltrexone (Vivitrol)

4 Chapter 3: Alcohol Use Disorder: Neurobiology, Assessment & Acute Withdrawal

3.1 AUD Neurobiology, Epidemiology, Screening Instruments (AUDIT, AUDIT-C, CAGE) & Laboratory Biomarkers 3.2 Alcohol Withdrawal Syndrome, CIWA-Ar Protocol, Symptom-Triggered Benzodiazepine Regimens & Delirium Tremens 3.3 Wernicke-Korsakoff Syndrome, High-Dose Parenteral Thiamine Protocols & Acute Medical Complications

5 Chapter 4: Medications for Alcohol Use Disorder (MAUD)

4.1 Oral and Injectable Naltrexone for AUD: Mechanism, Prescribing Protocols & Clinical Efficacy 4.2 Acamprosate Calcium: NMDA Modulation, Renal Dosing Parameters & Abstinence Maintenance 4.3 Disulfiram and Second-Line / Off-Label MAUDs: Topiramate, Gabapentin & Baclofen

6 Chapter 5: Stimulant, Sedative-Hypnotic & Synthetic Substance Use Disorders

5.1 Stimulant Use Disorder (Cocaine & Methamphetamine): Neurotoxicity, Medical Emergencies & Evidence-Based Interventions 5.2 Sedative, Hypnotic, and Anxiolytic Disorders: Dependence Physiology, Risks & Outpatient Tapering Protocols 5.3 Emerging Synthetic Drugs: Fentanyl Analogues, Synthetic Cathinones, Cannabinoids & Xylazine-Associated Necrotic Wounds

7 Chapter 6: Tobacco and Cannabis Use Disorders: Evidence-Based Pharmacotherapy & Interventions

6.1 Tobacco Use Disorder & Nicotine Dependence: Dual NRT, Varenicline & Bupropion Prescribing Protocols 6.2 Cannabis Use Disorder, Synthetic Cannabinoids & Cannabinoid Hyperemesis Syndrome 6.3 Behavioral Therapies in Substance Use: Motivational Interviewing, CBT & Contingency Management

8 Chapter 7: Psychiatric Differential Diagnosis & Medical Mimics in Addictions

7.1 Diagnostic Formulation: Primary vs. Substance-Induced Psychiatric Disorders & The 30-Day Rule 7.2 Endocrine, Neurological, and Metabolic Mimics of Substance Intoxication and Withdrawal 7.3 Decisional Capacity, Competency, and Involuntary Commitment in Acute Addiction Practice

9 Chapter 8: Co-Occurring Psychiatric Disorders: Integrated Treatment Planning

8.1 Integrated Dual Diagnosis Treatment (IDDT) Framework & High-Prevalence Mood / Anxiety Co-Occurring Disorders 8.2 Complex Severe Mental Illness: Psychotic Disorders, Bipolar Disorder & Borderline Personality in Addictions 8.3 Trauma-Informed Care, PTSD, and Addictions: Evidence-Based Integrated Psychotherapy

10 Chapter 9: Pain Management in Substance Use Disorders & CDC 2022 Guidelines

9.1 CDC 2022 Clinical Practice Guideline for Prescribing Opioids for Chronic Pain: Individualized Assessment vs. Hard Caps 9.2 Multimodal Non-Opioid Pharmacotherapy, Interventional Modalities & Non-Pharmacological Strategies 9.3 Acute Pain Management in Patients on Maintenance MOUD (Methadone, Buprenorphine, Naltrexone)

11 Chapter 10: Perinatal Substance Use, Neonatal Abstinence & Infectious Complications

10.1 Perinatal Substance Use Disorder: ACOG/ASAM Guidelines, MOTHER Trial & Maintenance MOUD 10.2 Neonatal Abstinence Syndrome (NAS/NOWS): Finnegan Scoring vs. Eat, Sleep, Console (ESC) & Breastfeeding 10.3 Infectious Complications in People Who Inject Drugs: Viral Hepatitis, HIV, Endocarditis & PrEP/PEP

12 Chapter 11: Federal Regulations, Confidentiality & Controlled Substance Prescribing

11.1 Controlled Substances Act, DEA Registration, Schedule Classifications & MAT Act of 2023 11.2 Confidentiality of Substance Use Disorder Patient Records: 42 CFR Part 2 (2024 Final Rule) & HIPAA Harmonization 11.3 Prescription Drug Monitoring Programs (PDMP) & Urine Drug Testing (UDT) Interpretation

13 Chapter 12: APRN Scope of Practice, Ethical Foundations, Harm Reduction & Research Literacy

12.1 APRN Scope of Practice, Prescriptive Authority & Collaborative Practice Regulations 12.2 Ethical Dilemmas in Addictions Nursing: Stigma, Autonomy, Justice, and Maternal/Fetal Rights 12.3 Harm Reduction Philosophy, Syringe Service Programs, Drug Checking & Overdose Prevention 12.4 Landmark Clinical Trials & Research Literacy in Addictions Medicine

14 Chapter 13: Stimulant Use Disorder in Depth — Methamphetamine, Withdrawal, Treatment & Harm Reduction

13.1 Methamphetamine Use Disorder: Pharmacology, Medical & Psychiatric Sequelae 13.2 Stimulant Withdrawal, Craving & Contingency Management 13.3 Pharmacotherapy Research for Stimulant Use Disorder 13.4 Stimulant Harm Reduction, Overamping & Patient Education

15 Chapter 14: Medical Consequences of Alcohol Use — Liver, Heart, Cancer & Nutrition

14.1 Alcohol-Associated Liver Disease: Staging, Scoring & Management 14.2 Cardiovascular, Oncologic & Nutritional Consequences of Alcohol

16 Chapter 15: Brief Intervention, Drinking Goals & Recovery Support in Alcohol Use Disorder

15.1 Brief Intervention, Drinking Goals & Shared Decision Making in AUD 15.2 Relapse Prevention, Mutual-Help Programs & Recovery Support

17 Chapter 16: Tobacco Use Disorder in Depth — Neurobiology, Assessment & Special Populations

16.1 Nicotine Neurobiology, Epidemiology & the Tobacco Product Landscape 16.2 Tobacco Assessment & Behavioral Treatment: 5 A's, Quitlines & Incentives 16.3 Tobacco Treatment in Special Populations & Co-Occurring Disorders

18 Chapter 17: Cannabis Use Disorder in Depth — Products, Treatment & Policy

17.1 Cannabinoid Pharmacology, Potency & the Modern Product Landscape 17.2 Cannabis Use Disorder: Epidemiology, Assessment & Treatment Evidence 17.3 Medical Cannabis, Legalization Policy, Adolescent Risk & Patient Education

19 Chapter 18: Other Use Disorders — Inhalants, Hallucinogens, Process Addictions & Prescription/OTC Misuse

18.1 Inhalant Use Disorder: Volatile Solvents, Nitrous Oxide & Alkyl Nitrites 18.2 Hallucinogens & Dissociatives: Classic Psychedelics, PCP, Ketamine & HPPD 18.3 Process (Behavioral) Addictions: Gambling Disorder, Gaming & Compulsive Behaviors 18.4 Prescription & Over-the-Counter Substance Misuse: Opioids, Stimulants, Kratom & DXM

20 Chapter 19: Educating Patients, Families & the Public (CARN-AP Activity Area III)

19.1 Designing Health Teaching: Literacy, Readiness, Culture & Teach-Back 19.2 Medication Education, Informed Consent & Informed Refusal 19.3 Family & Support-System Education: CRAFT, Al-Anon & Overdose Prevention Teaching 19.4 Public, Professional & Anticipatory Guidance: Prevention and Advocacy Teaching

21 Chapter 20: Consultation, Collaboration & Care Coordination (CARN-AP Activity Area IV)

20.1 The APRN Consultation Process & Communicating Recommendations 20.2 Interprofessional Collaboration, Care Coordination & Transitions of Care 20.3 Community Resources, Systems Navigation & Collaborative Documentation

22 Chapter 21: Quality Improvement, Evidence & Leadership in Addictions Nursing (CARN-AP Activity Area V)

21.1 Outcome Measurement & Continuous Quality Improvement in Addictions Care 21.2 Policy Advocacy, Leadership & the Determinants of Addiction

18.3 Process (Behavioral) Addictions: Gambling Disorder, Gaming & Compulsive Behaviors

Key Takeaways Explain This Topic AI

Gambling disorder is the only behavioral addiction placed in the DSM-5-TR substance-related and addictive disorders chapter, requiring 4 or more of 9 criteria within 12 months.

DSM-5-TR moved gambling disorder out of the impulse control disorders and removed the illegal acts criterion, leaving nine criteria rather than ten.

Internet gaming disorder remains in the DSM-5-TR Section III conditions for further study, while ICD-11 recognizes gaming disorder as a formal diagnosis.

Dopamine agonists used for Parkinson disease and restless legs syndrome cause impulse control disorders including pathological gambling, and the treatment is to reduce or stop the agonist.

Gambling disorder carries one of the highest suicide attempt rates of any psychiatric condition, so suicide risk assessment is mandatory at every contact.

Last updated: September 2026

18.3 Process (Behavioral) Addictions: Gambling Disorder, Gaming & Compulsive Behaviors

Quick Answer: Gambling disorder is the only behavioral addiction included in the DSM-5-TR chapter on substance-related and addictive disorders. It requires 4 or more of 9 criteria in a 12-month period. DSM-5 moved it out of impulse control disorders and deleted the illegal-acts criterion . Internet gaming disorder remains in Section III (conditions for further study) , while ICD-11 recognizes gaming disorder as a formal diagnosis. Dopamine agonists (pramipexole, ropinirole, rotigotine) cause iatrogenic gambling, and gambling disorder has among the highest suicide attempt rates in psychiatry .

The ANCB blueprint names process addictions explicitly within category E. Candidates who study only substances will miss these items.

1. Gambling Disorder: The Nine Criteria

Persistent and recurrent problematic gambling leading to clinically significant impairment or distress, with 4 or more of the following in 12 months:

  • Needs to gamble with increasing amounts of money to achieve the desired excitement ( tolerance )
  • Restless or irritable when attempting to cut down or stop ( withdrawal-like )
  • Repeated unsuccessful efforts to control, cut back or stop
  • Frequently preoccupied with gambling
  • Often gambles when feeling distressed
  • After losing money, often returns another day to get even ( "chasing" losses )
  • Lies to conceal the extent of involvement
  • Has jeopardized or lost a significant relationship, job, or educational or career opportunity
  • Relies on others to provide money to relieve desperate financial situations ( "bailout" )

Severity: mild 4 to 5 criteria; moderate 6 to 7; severe 8 to 9. Specify episodic or persistent , and in early remission (3 to under 12 months) or sustained remission (12 months or more).

Two changes candidates are tested on: DSM-5 reduced the criterion threshold from 5 to 4 , removed the illegal-acts criterion (leaving 9 rather than 10), and relocated the diagnosis from impulse control disorders into the addictive disorders chapter based on shared neurobiology, phenomenology, comorbidity and treatment response.

2. Screening

  • Tool Items Use
  • Lie/Bet questionnaire 2 Ultra-brief: ever lied about gambling; ever needed to bet more money
  • NODS-CLiP 3 Brief clinical screen

Problem Gambling Severity Index (PGSI) 9 Population and clinical severity; 8 or more indicates problem gambling

South Oaks Gambling Screen (SOGS) 20 Older, longer, still widely used

Ask about sports betting and in-app purchases specifically. Mobile sports wagering and in-game loot boxes have changed the epidemiology substantially, moving gambling onto a phone that is available continuously and shortening the interval between impulse and wager to seconds.

3. Comorbidity and Suicide Risk

High rates of co-occurring alcohol use disorder, tobacco use disorder, mood disorders, anxiety disorders and ADHD .

Suicide attempt rates in gambling disorder are among the highest of any psychiatric condition , driven by acute financial catastrophe, shame and concealment.

The financial crisis is frequently the presenting event: a spouse discovers hidden debt, a retirement account is emptied, or a bankruptcy is filed.

APRN obligation: screen for suicidal ideation at every contact, ask directly about firearm access, and involve the family when the patient consents, because the financial and safety plan usually requires someone else.

4. The Iatrogenic Cause You Must Rule Out

Dopamine agonists — pramipexole, ropinirole, rotigotine, and to a lesser extent levodopa and the dopamine partial agonist aripiprazole — cause impulse control disorders : pathological gambling, compulsive shopping, hypersexuality and binge eating. Features:

Onset after starting or increasing the agent, often in a person with no prior gambling history.

Frequently not volunteered by the patient because of shame; must be asked about directly at every medication review.

Treatment is to reduce or discontinue the dopamine agonist , in coordination with the prescribing neurologist or psychiatrist, after which the behavior usually remits.

Any new-onset gambling problem in a patient with Parkinson disease, restless legs syndrome, hyperprolactinemia, or on aripiprazole should trigger this review before any other intervention.

5. Treatment

Modality Evidence

Cognitive behavioral therapy Best-supported treatment; targets cognitive distortions (illusion of control, gambler's fallacy, near-miss effect, selective recall of wins)

  • Motivational interviewing Effective for engagement, often combined with CBT
  • Gamblers Anonymous Twelve-step mutual help; GamAnon for family members

Self-exclusion programs Voluntary casino and sportsbook bans; app blockers and bank gambling-transaction blocks

Financial counseling and restructuring Essential and frequently omitted; removing access to funds is a concrete relapse-prevention intervention

Naltrexone 50 to 100 mg daily Randomized data support benefit, especially with a family history of alcoholism; not FDA-approved for this indication

  • Nalmefene Positive trials; not marketed in the United States for this use
  • Lithium Some benefit in gambling with bipolar spectrum comorbidity
  • SSRIs Inconsistent; treat comorbid depression or anxiety rather than gambling itself

No medication is FDA-approved for gambling disorder. The defensible plan is CBT plus mutual help plus financial access restriction, with naltrexone as an off-label adjunct when craving is prominent.

6. Gaming and Other Proposed Behavioral Addictions

Condition Status

Internet gaming disorder DSM-5-TR Section III , conditions for further study; proposed 9 criteria with a threshold of 5

Gaming disorder Recognized in ICD-11 — impaired control, increasing priority over other interests, continuation despite negative consequences, usually for at least 12 months

Compulsive sexual behavior disorder Recognized in ICD-11 as an impulse control disorder, deliberately not classified as an addiction

Compulsive buying, exercise, and food addiction Not recognized diagnoses; described in the literature but without formal criteria

Exam trap: "sex addiction" and "food addiction" are not DSM-5-TR diagnoses. Compulsive sexual behavior disorder exists in ICD-11 but as an impulse control disorder, explicitly not as an addictive disorder. Only gambling disorder sits in the DSM addictive disorders chapter.